Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP & Chief Scientific Officer | April 03, 2019 | April 05, 2019 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| Natera, Inc.NTRA · Entity 2635 | Director | June 26, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date April 03, 2019 · Filed April 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 22,222.964 |
Ending reported balance
After 2019-04-03 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2019-04-03 · Exercise / conversion · Acquired 6,296 · Balance 23,868.964 Row 2 · 2019-04-03 · Tax withholding · Disposed 3,351 · Balance 20,517.964 F1: Shares withheld for payment of taxes upon vesting of awards. Row 3 · 2019-04-03 · Exercise / conversion · Acquired 5,298 · Balance 25,815.964 F2: Represents vesting of one-quarter of market share units granted on April 3, 2017. Row 4 · 2019-04-03 · Other · Disposed 773 · Balance 25,042.964 F3: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 5 · 2019-04-03 · Tax withholding · Disposed 2,820 · Balance 22,222.964 F1: Shares withheld for payment of taxes upon vesting of awards. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2021-04-03 | Direct | 12,592 |
Reported balance
After 2019-04-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-04-03 · Exercise / conversion · Disposed 6,296 · Balance 12,592 F4: Each restricted stock unit converts into one share of common stock upon vesting. F5: Represents vesting of one-quarter of restricted stock units granted on April 3, 2017. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2021-04-03 | Direct | 12,143 |
Reported balance
After 2019-04-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-04-03 · Exercise / conversion · Disposed 5,298 · Balance 12,143 F6: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2: Represents vesting of one-quarter of market share units granted on April 3, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld for payment of taxes upon vesting of awards.
F2: Represents vesting of one-quarter of market share units granted on April 3, 2017.
F3: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
F4: Each restricted stock unit converts into one share of common stock upon vesting.
F5: Represents vesting of one-quarter of restricted stock units granted on April 3, 2017.
F6: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Natera, Inc.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,905 |
Reported balance
After 2026-06-26 transaction · row 1
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 1,905 · Balance 1,905 F1: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in the amount of $425,000. The RSUs will vest in three equal annual installments beginning on June 2, 2027. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in the amount of $425,000. The RSUs will vest in three equal annual installments beginning on June 2, 2027.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jul 1, 2026 00:05 UTC | Natera, Inc. NTRA · Entity 2635 | GrantCommon Stock | 1,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001474056-26-000008 · form4-06302026_080608.xml · nonDerivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,905 F1 · shares: Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person in the amount of $425,000. The RSUs will vest in three equal annual installments beginning on June 2, 2027. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:06 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 28,000 | $4.08 Strike: $4.08 | $114,240.00 |
DisclosureSEC source: 0001474056-26-000007 · primarydocument.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:28 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 25,000 | $4.79 Strike: $4.79 | $119,750.00 |
DisclosureSEC source: 0001562180-25-004906 · primarydocument.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-16 Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:06 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $5.52 Strike: $5.52 | $88,320.00 |
DisclosureSEC source: 0001562180-24-005360 · primarydocument.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-25 Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 00:14 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005480 · primarydocument.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-20 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 20:04 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 32,000 | $8.23 Strike: $8.23 | $263,360.00 |
DisclosureSEC source: 0001562180-22-007379 · primarydocument.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2032-10-26 F1 · derivative.exercise_date: The options will vest as to one-third of the underlying shares of common stock on each of the first three anniversaries of the date of grant, subject to the recipient's continuing service on the board of directors. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 5,298 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000102 · wf-form4_155449634349912.xml · derivative · entry 7 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,143 Underlying: Common Stock, $0.10 par value · 5,298 shares Expires 2021-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on April 3, 2017. F2 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on April 3, 2017. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 6,296 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000102 · wf-form4_155449634349912.xml · derivative · entry 6 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,592 Underlying: Common Stock, $0.10 par value · 6,296 shares Expires 2021-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F5 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on April 3, 2017. F5 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on April 3, 2017. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,820 | $46.88 | $132,201.60 |
DisclosureSEC source: 0000014272-19-000102 · wf-form4_155449634349912.xml · nonDerivative · entry 5 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,222.964 F1 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000102 · wf-form4_155449634349912.xml · nonDerivative · entry 4 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,042.964 F3 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 5,298 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000102 · wf-form4_155449634349912.xml · nonDerivative · entry 3 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,815.964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents vesting of one-quarter of market share units granted on April 3, 2017. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,351 | $46.88 | $157,094.88 |
DisclosureSEC source: 0000014272-19-000102 · wf-form4_155449634349912.xml · nonDerivative · entry 2 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,517.964 F1 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,296 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000102 · wf-form4_155449634349912.xml · nonDerivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,868.964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2019 Filed Mar 13, 2019 11:36 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 44,865 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000073 · wf-form4_155247697557354.xml · derivative · entry 6 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,865 Underlying: Common Stock, $0.10 par value · 44,865 shares Expires 2022-03-10 F6 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2022. F6 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2022. F6 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2022. Read SEC document |
| March 10, 2019 Filed Mar 13, 2019 11:36 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 29,910 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000073 · wf-form4_155247697557354.xml · derivative · entry 5 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,910 Underlying: Common Stock, $0.10 par value · 29,910 shares Expires 2023-03-10 F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5 · derivative.exercise_date: Twenty-five percent of these market share units will vest on each of the first, second, third, and fourth anniversaries of the grant date F5 · derivative.expiration_date: Twenty-five percent of these market share units will vest on each of the first, second, third, and fourth anniversaries of the grant date Read SEC document |
| March 10, 2019 Filed Mar 13, 2019 11:36 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 5,864 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000073 · wf-form4_155247697557354.xml · derivative · entry 4 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,593 Underlying: Common Stock, $0.10 par value · 5,864 shares Expires 2022-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2018. F1 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 10, 2018. Read SEC document |
| March 10, 2019 Filed Mar 13, 2019 11:36 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,383 | $51.39 | $122,462.37 |
DisclosureSEC source: 0000014272-19-000073 · wf-form4_155247697557354.xml · nonDerivative · entry 3 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,572.964 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2019 Filed Mar 13, 2019 11:36 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 1,387 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000073 · wf-form4_155247697557354.xml · nonDerivative · entry 2 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,955.964 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2019 Filed Mar 13, 2019 11:36 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 5,864 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-19-000073 · wf-form4_155247697557354.xml · nonDerivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,342.964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2018. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 6,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-18-000109 · wf-form4_152296060397015.xml · derivative · entry 7 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,214 Underlying: Common Stock, $0.10 par value · 6,071 shares Expires 2021-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on April 3, 2017. F2 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on April 3, 2017. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 6,296 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-18-000109 · wf-form4_152296060397015.xml · derivative · entry 6 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,888 Underlying: Common Stock, $0.10 par value · 6,296 shares Expires 2021-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F5 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on April 3, 2017. F5 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on April 3, 2017. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,737 | $62.77 | $234,571.49 |
DisclosureSEC source: 0000014272-18-000109 · wf-form4_152296060397015.xml · nonDerivative · entry 5 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,478.964 F1 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 949 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-18-000109 · wf-form4_152296060397015.xml · nonDerivative · entry 4 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,215.964 F3 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-18-000109 · wf-form4_152296060397015.xml · nonDerivative · entry 3 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,266.964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents vesting of one-quarter of market share units granted on April 3, 2017. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,351 | $62.77 | $210,342.27 |
DisclosureSEC source: 0000014272-18-000109 · wf-form4_152296060397015.xml · nonDerivative · entry 2 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,195.964 F1 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,296 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-18-000109 · wf-form4_152296060397015.xml · nonDerivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,546.964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 20:55 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 35,186 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-18-000082 · wf-form4_152097452966258.xml · derivative · entry 2 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,186 Underlying: Common Stock, $0.10 par value · 35,186 shares Expires 2021-03-10 F3 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2021. F3 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2021. F3 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2021. Read SEC document |
| March 10, 2018 Filed Mar 13, 2018 20:55 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 23,457 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-18-000082 · wf-form4_152097452966258.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,457 Underlying: Common Stock, $0.10 par value · 23,457 shares Expires 2022-03-10 F1 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F2 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. F2 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 22:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 5,300 | $63.24 | $335,172.00 |
DisclosureSEC source: 0000014272-17-000206 · wf-form4_151320424860165.xml · nonDerivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250.964 F1 · shares: These shares were sold to cover taxes in connection with the settlement of Deferred Share Units. Deferred Share Units convert into a share of common stock upon settlement. Read SEC document |
| May 14, 2017 Filed Jun 8, 2017 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionDeferred Share Units · Derivative | 14,550.964 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000142 · wf-form4_149695506322084.xml · derivative · entry 2 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 14,550.964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors earned for service as a Director prior to Dr. Lynch's retirement from the Board on March 15, 2017. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| May 14, 2017 Filed Jun 8, 2017 20:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 14,550.964 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000142 · wf-form4_149695506322084.xml · nonDerivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,550.964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 21:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 36,427 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000123 · wf-form4_149142625856582.xml · derivative · entry 3 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,427 Underlying: Common Stock, $0.10 par value · 36,427 shares Expires 2020-03-10 F5 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2020. F5 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2020. F5 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2020. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 21:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 24,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000123 · wf-form4_149142625856582.xml · derivative · entry 2 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,285 Underlying: Common Stock, $0.10 par value · 24,285 shares Expires 2021-04-03 F3 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 21:04 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 25,184 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-17-000123 · wf-form4_149142625856582.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,184 Underlying: Common Stock, $0.10 par value · 25,184 shares Expires 2021-04-03 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on April 3, 2018. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on April 3, 2018. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 23:18 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 115.763 | $54.38 | $6,295.19 |
DisclosureSEC source: 0000014272-17-000114 · wf-form4_149134791969036.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,451.674 Underlying: Common Stock, $0.10 par value · 115.763 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents Deferred Share Units earned for service as a Director prior to Dr. Lynch's retirement from the Board of Directors on March 15, 2017. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · derivative.underlying_shares: Represents Deferred Share Units earned for service as a Director prior to Dr. Lynch's retirement from the Board of Directors on March 15, 2017. F3 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 22:19 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 3,448.975 | $49.29 | $169,999.98 |
DisclosureSEC source: 0000014272-17-000034 · wf-form4_148616032970054.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,335.911 Underlying: Common Stock, $0.10 par value · 3,448.975 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2016 Filed Jan 5, 2017 01:21 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 131.01 | $58.44 | $7,656.22 |
DisclosureSEC source: 0000014272-17-000012 · wf-form4_148357926203398.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,801.471 Underlying: Common Stock, $0.10 par value · 131.01 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 21:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 141.993 | $53.92 | $7,656.26 |
DisclosureSEC source: 0000014272-16-000480 · wf-form4_147561786191748.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,591.235 Underlying: Common Stock, $0.10 par value · 141.993 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2016 Filed Jul 5, 2016 22:56 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 104.096 | $73.55 | $7,656.26 |
DisclosureSEC source: 0000014272-16-000442 · wf-form4_146775940264531.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,397.385 Underlying: Common Stock, $0.10 par value · 104.096 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2016 Filed Apr 4, 2016 21:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 119.854 | $63.88 | $7,656.27 |
DisclosureSEC source: 0000014272-16-000382 · wf-form4_145980368261392.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,239.222 Underlying: Common Stock, $0.10 par value · 119.854 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2016 Filed Feb 3, 2016 21:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,795.133 | $60.82 | $169,999.99 |
DisclosureSEC source: 0000014272-16-000271 · wf-form4_145453669718827.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,119.368 Underlying: Common Stock, $0.10 par value · 2,795.133 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2015 Filed Jan 5, 2016 23:22 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 102.213 | $68.79 | $7,031.23 |
DisclosureSEC source: 0000014272-16-000253 · wf-form4_145203610984133.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,278.757 Underlying: Common Stock, $0.10 par value · 102.213 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2015 Filed Oct 2, 2015 20:40 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 118.771 | $59.20 | $7,031.24 |
DisclosureSEC source: 0000014272-15-000224 · wf-form4_144381842529622.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,136.385 Underlying: Common Stock, $0.10 par value · 118.771 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2015 Filed Jul 1, 2015 21:07 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 105.67 | $66.54 | $7,031.28 |
DisclosureSEC source: 0000014272-15-000201 · wf-form4_143578483275952.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,978.099 Underlying: Common Stock, $0.10 par value · 105.67 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2015 Filed Apr 2, 2015 21:53 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 109.01 | $64.50 | $7,031.15 |
DisclosureSEC source: 0000014272-15-000168 · wf-form4_142801157791976.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,833.33 Underlying: Common Stock, $0.10 par value · 109.01 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 01, 2015 Filed Feb 3, 2015 23:16 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,654.72 | $60.27 | $159,999.97 |
DisclosureSEC source: 0000014272-15-000038 · wf-form4_142300539963352.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,724.32 Underlying: Common Stock, $0.10 par value · 2,654.72 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2014 Filed Jan 6, 2015 00:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 118.07 | $59.55 | $7,031.07 |
DisclosureSEC source: 0000014272-15-000007 · wf-form4_142050468372239.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,044.75 Underlying: Common Stock, $0.10 par value · 118.07 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2014 Filed Oct 2, 2014 20:45 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 136.4 | $51.55 | $7,031.42 |
DisclosureSEC source: 0000014272-14-000238 · wf-form4_141228271611928.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,876.39 Underlying: Common Stock, $0.10 par value · 136.4 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2014 Filed Jul 2, 2014 22:02 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 140.26 | $48.83 | $6,848.90 |
DisclosureSEC source: 0000014272-14-000196 · wf-form4_140433854769075.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,713.44 Underlying: Common Stock, $0.10 par value · 140.26 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2014 Filed Apr 2, 2014 11:51 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 126.2 | $52.00 | $6,562.40 |
DisclosureSEC source: 0000014272-14-000158 · wf-form4_139643950010072.xml · derivative · entry 1 Lynch Thomas J. Jr. · CIK 0001474056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,573.04 Underlying: Common Stock, $0.10 par value · 126.2 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.